Business
Notice of AGM and posting of Annual Report
Notice of AGM and posting of Annual Report.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\nPosting of Annual Report and AGM Notice\n \n6 December 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), the life science business focused on skin health confirms that the Notice of Annual General Meeting (\"AGM\"), form of proxy and Annual Report and Accounts for the year ended 30 June 2023 have been posted to shareholders.\n \nAn electronic copy of the Annual Report and Accounts and the Notice of AGM are also available on the Company's website - www.skinbiotherapeutics.com/investor-relations.\n \nThe AGM will be held at 9:00am on Friday 29 December 2023 at The Clarion Hotel, Witney Way, Boldon, NE35 9PE.\n \n-Ends-\n \nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n\n\nTel: +44 (0) 191 495 7325\n \n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser & Broker)\nGiles Balleny, Dan Hodkinson\n(Corporate Finance)\nCharlie Combe (Broking)\nDale Bellis, Tamar Cranford-Smith (Sales)\n \n\n\nTel: +44 (0) 20 7220 0500\n \n\n\n\n\nInstinctif Partners (financial press)\nMelanie Toyne-Sewell / Jack Kincade\n \n\n\nTel: +44 (0) 20 7457 2020\[email protected]\n \n\n\n\n\n \nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.\nThe Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.\nThe Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.\n \n \n\n","length":5674,"tagName":"div"}]